Could Gilead Sciences Stock Help You Become a Millionaire?

Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend. Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration. With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue.